Gilead Sciences (GILD) stock fell after The Wall Street Journal reported that the Health and Human Services Department is looking at ...

The EU drugs regulator says Gilead Sciences’ antiviral drug remdesivir ... and its chief executive Daniel O’Day said at the weekend it now has 1.5 million doses, enough to treat around 140,000 ...

Gilead Sciences has taken a major step towards ... HIV in combination with other antiretrovirals. In a statement, Daniel O’Day, chairman and chief executive officer at Gilead, highlighted ...

Daniel Slim / AFP / Getty The S&P 500 added ... Shares of biopharmaceutical company Gilead Sciences (GILD) fell 2.5% following reports that the Department of Health and Human Services is ...

The Health and Human Services Department is considering cuts to HIV prevention funding, according to The Wall Street Journal.

Change value during the period between open outcry settle and the commencement of the next day's trading is calculated as the difference between the last trade and the prior day's settle.

A pharmacist holds a vial of lenacapavir, Gilead's HIV prevention drug. (Nardus Engelbrecht/Associated Press) Gilead Sciences has been one of the best-performing ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...